Biocure Technology (CSE:CURE, OTCQB:BICTF)
Biocure Technology (CSE:CURE, OTCQB:BICTF)
Biotechnology research
Sector
Front runner in CAR-T cell therapy for cancer patients

Business Highlights

Biocure Pharma is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer. Headquartered in Korea, Biocure Pharma has joint venture partners in Asia and Europe with planned clinical trials commencing in 2021. Biocure is listed on both the Canadian Stock Exchange and OTC Markets.

CAR-T cell therapy is regarded as a cancer breakthrough. UPenn completed a study of 30 children and adults receiving a single injection of CAR-T cell therapy and 90% went into complete remission. This led to the U.S. FDA approving Kymriah®, a CAR-T cell therapy offered to leukemia patients for US$475,000 per dose.

Biocure Pharma is planning its Phase I & II clinical trials for its CAR-T cell therapy, BCP401 (leukemia), with the aim of launching to market in Korea by end 2022. Korea represents a US$2 billion p.a market for leukemia with substantial upside potential in Asia and Europe.

An investigator clinical trial was conducted at Beijing University Hospital in China using a CAR-T cell therapy provided by Pharos Vaccine, a research and development company of Biocure Pharma. The CAR-T program had a good response with a single dose.

The overall response rate was 55 of 56 subjects (98.21%) and complete remission in 53 of 56 (94.64%), superior to current FDA- approved CAR-T therapies. All patients were alive for 3 months.Complete Remission after BCP401

Biocure Pharma has also entered into a JV in Germany to progress its CAR-T cell therapy, BCP402 for lung, breast and pancreatic cancer. This, together with BCP401, provides numerous inflection points over the coming 24 months, as Biocure Pharma brings these therapies to market.

Financials

The Company in late July 2021 successfully completed a C$1.1M equity raise and is on track to achieve multiple key goals in 2021.

Announcements

Closing of Financing

Read more

Dual listing in Germany and new contracts

Read more

Biocure Technology Inc. Announces Focus on its own CAR T-cell Therapy

Read more

Team

Sang Mok Lee

CEO & President, Director

Konstantin Lichtenwald

CFO, Director

Collin (Sang Goo) Kim

Director

Berkan Unal

Director

Danny Joh

Director

Jae Soo Shin

PHD

Heon Ju Lee

PHD

Hyun Soo Lee

PHD

image

WOTSO

Real estate

image

Water Licence

Utilities

image

VCU Carbon Credits

Industrials

image

Virtual Home Loan Marketplace

Diversified Financial Services

image

TOR Mining Capital Limited

Metals & Mining

image

Tyro Payments Limited (ASX.TYR)

Diversified Financial Services

image

Tin International (GER)

Metals & Mining

image

Sydney Outback

Consumer Services

image

Stepps Private Equity Partners

Diversified Financial Services

image

Online Payments

Diversified Financial Services

image

Music Licensing Platform (USA)

image

Lime (USA)

Information Technology

    Thank you for your enquiry.
    We will be in touch as soon as possible.